An update on pharmacologic treatments for autism spectrum disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 15, Issue 1, 2006, Pages 161-175

  King, Bryan H ^a   Bostic, Jeff Q ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CLONIDINE; CYCLOSERINE; DIAZEPAM; DONEPEZIL; ESCITALOPRAM; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; ANXIETY; AUTISM; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEART RATE VARIABILITY; HUMAN; HYPERPHAGIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; MANIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHOLINERGIC AGENTS; HUMANS; NARCOTICS;

EID: 28444458056     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2005.08.005     Document Type: Review

References (78)

1. C.J. Newschaffer, M.D. Falb, and J.G. Gurney National autism prevalence trends from United States special education data Pediatrics 115 3 2005 e277 e282
2. J. Merrick, I. Kandel, and M. Morad Trends in autism Int J Adolesc Med Health 16 1 2004 75 78
3. H. Jick, and J.A. Kaye Epidemiology and possible causes of autism Pharmacotherapy 23 12 2003 1524 1530
4. H. Honda, Y. Shimizu, and M. Imai Cumulative incidence of childhood autism: a total population study of better accuracy and precision Dev Med Child Neurol 47 1 2005 10 18
5. M.B. Lauritsen, C.B. Pedersen, and P.B. Mortensen The incidence and prevalence of pervasive developmental disorders: a Danish population-based study Psychol Med 34 7 2004 1339 1346
6. E. Fombonne Epidemiological surveys of autism and other pervasive developmental disorders: an update J Autism Dev Disord 33 4 2003 365 382
7. D.S. Mandell, W.W. Thompson, and E.S. Weintraub Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnoses Psychiatr Serv 56 1 2005 56 62
8. T.D. Challman, W.J. Barbaresi, and S.K. Katusic The yield of the medical evaluation of children with pervasive developmental disorders J Autism Dev Disord 33 2 2003 187 192
9. S. Baron-Cohen, S. Wheelwright, and A. Cox Early identification of autism by the CHecklist for Autism in Toddlers (CHAT) J R Soc Med 93 10 2000 521 525
10. D. Cohen, N. Pichard, and S. Tordjman Specific genetic disorders and autism: clinical contribution towards their identification J Autism Dev Disord 35 1 2005 103 116
11. T.H. Wassink, L.M. Brzustowicz, and C.W. Bartlett The search for autism disease genes Ment Retard Dev Disabil Res Rev 10 4 2004 272 283
12. E. Courchesne, and K. Pierce Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity Int J Dev Neurosci 23 2-3 2005 153 170
13. E. Courchesne, R. Carper, and N. Akshoomoff Evidence of brain overgrowth in the first year of life in autism JAMA 290 3 2003 337 344
14. K.A. Pelphrey, J.P. Morris, and G. McCarthy Neural basis of eye gaze processing deficits in autism Brain 128 Pt 5 2005 1038 1048
15. K.M. Dalton, B.M. Nacewicz, and T. Johnstone Gaze fixation and the neural circuitry of face processing in autism Nat Neurosci 8 4 2005 519 526
16. P.A. Filipek, J. Juranek, and M.T. Nguyen Relative carnitine deficiency in autism J Autism Dev Disord 34 6 2004 615 623
17. G. Oliveira, L. Diogo, and M. Grazina Mitochondrial dysfunction in autism spectrum disorders: a population-based study Dev Med Child Neurol 47 3 2005 185 189
18. N. Barnea-Goraly, H. Kwon, and V. Menon White matter structure in autism: preliminary evidence from diffusion tensor imaging Biol Psychiatry 55 3 2004 323 326
19. M.K. Belmonte, E.H. Cook Jr, and G.M. Anderson Autism as a disorder of neural information processing: directions for research and targets for therapy (1) Mol Psychiatry 9 7 2004 646 663
20. G.M. McAlonan, V. Cheung, and C. Cheung Mapping the brain in autism. A voxel-based MRI study of volumetric differences and intercorrelations in autism Brain 128 Pt 2 2005 268 276
21. K. Horvath, G. Stefanatos, and K.N. Sokolski Improved social and language skills after secretin administration in patients with autistic spectrum disorders J Assoc Acad Minor Phys 9 1 1998 9 15
22. P. Sturmey Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials Res Dev Disabil 26 1 2005 87 97
23. B.H. King Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders J Autism Dev Disord 30 5 2000 439 445
24. S. Goldstein, and A.J. Schwebach The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: results of a retrospective chart review J Autism Dev Disord 34 3 2004 329 339
25. E. Hollander, A.T. Phillips, and C.C. Yeh Targeted treatments for symptom domains in child and adolescent autism Lancet 362 9385 2003 732 734
26. C.J. McDougle, L. Scahill, and J.T. McCracken Research Units on Pediatric Psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone Child Adolesc Psychiatr Clin N Am 9 1 2000 201 224
27. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 2 Suppl 1999 106S 115S
28. L. Barnard, A.H. Young, J. Pearson, and J. Geddes A systematic review of the use of atypical antipsychotics in autism J Psychopharmacol 16 1 2002 93 101
29. J.T. McCracken, J. McGough, and B. Shah Risperidone in children with autism and serious behavioral problems N Engl J Med 347 5 2002 314 321
30. S. Shea, A. Turgay, and A. Carroll Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders Pediatrics 114 5 2004 e634 e641
31. A. Martin, L. Scahill, and G.M. Anderson Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data Am J Psychiatry 161 6 2004 1125 1127
32. M.S. Buchsbaum, E. Hollander, and M.M. Haznedar Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study Int J Neuropsychopharmacol 4 2 2001 119 125
33. C.J. McDougle, S.T. Naylor, and D.J. Cohen A double-blind, placebo-controlled study of Lamictal in adults with autistic disorder Arch Gen Psychiatry 53 11 1996 1001 1008
34. E. Hollander, A. Phillips, and W. Chaplin A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism Neuropsychopharmacology 30 3 2005 582 589
35. C.J. McDougle, L.E. Kresch, and D.J. Posey Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors J Autism Dev Disord 30 5 2000 427 435
36. A. Martin, K. Koenig, and G.M. Anderson Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study J Autism Dev Disord 33 1 2003 77 85
37. C.J. McDougle, E.S. Brodkin, and S.T. Naylor Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation J Clin Psychopharmacol 18 1 1998 62 66
38. R.J. Steingard, B. Zimnitzky, and D.R. DeMaso Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder J Child Adolesc Psychopharmacol 7 1 1997 9 15
39. D.I. Posey, M. Litwiller, and A. Koburn Paroxetine in autism J Am Acad Child Adolesc Psychiatry 38 2 1999 111 112
40. J.L. Couturier, and R. Nicolson A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders J Child Adolesc Psychopharmacol 12 3 2002 243 248
41. L.B. Namerow, P. Thomas, and J.Q. Bostic Use of citalopram in pervasive developmental disorders J Dev Behav Pediatr 24 2 2003 104 108
42. T. Owley, L. Walton, and J. Salt An open-label trial of escitalopram in pervasive developmental disorders J Am Acad Child Adolesc Psychiatry 44 4 2005 343 348
43. D.J. Posey, K.D. Guenin, and A.E. Kohn A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders J Child Adolesc Psychopharmacol 11 3 2001 267 277
44. E. Hollander, A. Kaplan, and C. Cartwright Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report J Child Neurol 15 2000 132 135
45. M. Aman, K.S. Lam, and M.E. Van Bourgondien Medication patterns in patients with autism: temporal, regional, and demographic influences J Child Adolesc Psychopharmacol 15 1 2005 116 126
46. A. Martin, L. Scahill, and A. Klin Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use J Am Acad Child Adolesc Psychiatry 38 7 1999 923 931
47. G.R. DeLong, C.R. Ritch, and S. Burch Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement Dev Med Child Neurol 44 10 2002 652 659
48. K.N. Sokolski, A. Chicz-Demet, and E.M. Demet Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series J Child Adolesc Psychopharmacol 14 1 2004 143 147
49. R.P. Malone, J. Cater, and R.M. Sheikh Olanzapine versus haloperidol in children with autistic disorder: an open pilot study J Am Acad Child Adolesc Psychiatry 40 8 2001 887 894
50. C. Kemner, S.H. Willemsen-Swinkels, and M. de Jonge Open-label study of olanzapine in children with pervasive developmental disorder J Clin Psychopharmacol 22 5 2002 455 460
51. R.L. Findling, N.K. McNamara, and B.L. Gracious Quetiapine in nine youths with autistic disorder J Child Adolesc Psychopharmacol 14 2 2004 287 294
52. A. Martin, K. Koenig, and L. Scahill Open-label quetiapine in the treatment of children and adolescents with autistic disorder J Child Adolesc Psychopharmacol 9 2 1999 99 107
53. A.H. Corson, J.E. Barkenbus, and D.J. Posey A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders J Clin Psychiatry 65 11 2004 1531 1536
54. C.J. McDougle, D.L. Kem, and D.J. Posey Case series: use of ziprasidone for maladaptive symptoms in youths with autism J Am Acad Child Adolesc Psychiatry 41 8 2002 921 927
55. S.A. Cohen, B.J. Fitzgerald, and S.R. Khan The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment J Clin Psychiatry 65 1 2004 110 113
56. K.A. Stigler, D.J. Posey, and C.J. McDougle Aripiprazole for maladaptive behavior in pervasive developmental disorders J Child Adolesc Psychopharmacol 14 3 2004 455 463
57. K.A. Stigler, M.N. Potenza, and D.J. Posey Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management Paediatr Drugs 6 1 2004 33 44
58. R. Canitano Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders Brain Dev 27 3 2005 228 232
59. A. Gagliano, E. Germano, and G. Pustorino Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications J Child Adolesc Psychopharmacol 14 1 2004 39 47
60. A.Y. Hardan, and B.L. Handen A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder J Child Adolesc Psychopharmacol 12 3 2002 237 241
61. M. Hertzman Galantamine in the treatment of adult autism: a report of three clinical cases Int J Psychiatry Med 33 4 2003 395 398
62. M.G. Chez, M. Aimonovitch, and T. Buchanan Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate J Child Neurol 19 3 2004 165 169
63. F. Marrosu, G. Marrosu, and M.G. Rachel Paradoxical reactions elicited by diazepam in children with classic autism Funct Neurol 2 3 1987 355 361
64. J. Barron, and C.A. Sandman Relationship of sedative-hypnotic response to self-injurious behavior and stereotypy by mentally retarded clients Am J Ment Defic 88 2 1983 177 186
65. J.A. Wray, J.H. Yoon, and T. Vollmer Pilot study of the behavioral effects of flumazenil in two children with autism J Autism Dev Disord 30 6 2000 619 620
66. M. Angehagen, E. Ben-Menachem, and L. Ronnback Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate Neurochem Res 28 2 2003 333 340
67. A.Y. Hardan, R.J. Jou, and B.L. Handen A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders J Child Adolesc Psychopharmacol 14 3 2004 426 432
68. B.H. King, D.M. Wright, and B.L. Handen Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder J Am Acad Child Adolesc Psychiatry 40 6 2001 658 665
69. K.M. Belsito, P.A. Law, and K.S. Kirk Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial J Autism Dev Disord 31 2 2001 175 181
70. D.J. Posey, D.L. Kem, and N.B. Swiezy A pilot study of d-cycloserine in subjects with autistic disorder Am J Psychiatry 161 11 2004 2115 2117
71. D.J. Posey, J.I. Puntney, and T.M. Sasher Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases J Child Adolesc Psychopharmacol 14 2 2004 233 241
72. U.C. Mehta, I. Patel, and F.V. Castello EEG sedation for children with autism J Dev Behav Pediatr 25 2 2004 102 104
73. J. Panksepp, N. Najam, and F. Soares Morphine reduces social cohesion in rats Pharmacol Biochem Behav 11 2 1979 131 134
74. P.G. Williams, A. Allard, and L. Sears Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management J Autism Dev Disord 31 1 2001 103 108
75. A. Di Martino, G. Melis, and C. Cianchetti Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study J Child Adolesc Psychopharmacol 14 2 2004 207 218
76. B.L. Handen, C.R. Johnson, and M. Lubetsky Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder J Autism Dev Disord 30 3 2000 245 255
77. J.B. Adams, and C. Holloway Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder J Altern Complement Med 10 6 2004 1033 1039
78. J.K. Ghuman, M.D. Cataldo, and M.H. Beck Behavioral training for pill-swallowing difficulties in young children with autistic disorder J Child Adolesc Psychopharmacol 14 4 2004 601 611